Baird Comments on Genzyme (GENZ), Saying CMS Reversed Prior Negative Decision
Tweet
Share
E-mailGet Alerts GENZ Hot Sheet
Price: $39.44 -0.98%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 20
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 20
Join SI Premium – FREE
CONTRIBUTOR http://notablecalls.blogspot.com
Baird commenting Genzyme (NASDAQ: GENZ), saying that they understand from GENZ that CMS has reversed its prior negative decision (announced in October) to cut Synvisc reimbursement by grouping all viscosupplementation products into one J-code in 2007.
A quick look at the CMS website confirms this positive development. Synvisc reimbursement will be $198/dose (three doses required per course), comparable to the 2006 level.
Orthovisc - Synvisc's closest comp in the category - is reimbursed at $200.54/dose, making the economics fairly comparable across the board.
As things stand today, Synvisc will no longer be unprofitable for physicians to administer, eliminating the need for a dramatic price decrease.
Based on this development, firm is raising their Synvisc revenue estimates to $266M from $229M, resulting in a new 2007 EPS estimate of $3.17.
Notablecalls: The negative reimpursement decision came out 30/10, initially sending the stock down 2 points. Simple logic makes me to expect the same upside today
Go To http://notablecalls.blogspot.com for More
Baird commenting Genzyme (NASDAQ: GENZ), saying that they understand from GENZ that CMS has reversed its prior negative decision (announced in October) to cut Synvisc reimbursement by grouping all viscosupplementation products into one J-code in 2007.
A quick look at the CMS website confirms this positive development. Synvisc reimbursement will be $198/dose (three doses required per course), comparable to the 2006 level.
Orthovisc - Synvisc's closest comp in the category - is reimbursed at $200.54/dose, making the economics fairly comparable across the board.
As things stand today, Synvisc will no longer be unprofitable for physicians to administer, eliminating the need for a dramatic price decrease.
Based on this development, firm is raising their Synvisc revenue estimates to $266M from $229M, resulting in a new 2007 EPS estimate of $3.17.
Notablecalls: The negative reimpursement decision came out 30/10, initially sending the stock down 2 points. Simple logic makes me to expect the same upside today
Go To http://notablecalls.blogspot.com for More
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Rosenblatt on SMCI: 'We believe the fundamental setup remains compelling'
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
Create E-mail Alert Related Categories
Analyst Comments, ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
